Muscle Dysfunction in Patients With Haematological Diseases

Rigshospitalet

Status: Active, not recruiting

Conditions: Acute Lymphoid Leukemia; Lymphoma; Myelodysplastic Syndromes; Acute Myeloid Leukemia; Hematologic Diseases

Study type: Observational

Funder types: Other

Identifiers

NCT05150561

MuscleLab2020

Details and patient eligibility

About

PURPOSE: To evaluate the prevalence and prognostic value of sarcopenia in patients diagnosed with hematological cancer diseases.

Full description

Some patients diagnosed with malignant hematological diseases are faced with poor prognosis and thus must undergo a demanding course of treatment associated with severe deconditioning potentially leading to worse prognostic outcomes. It is currently not well-described, to what extend patients body composition at the point of diagnoses should be part of standard clinical evaluation in order to optimize therapy-efficacy. Recent findings suggest that pathophysiological alterations in skeletal muscle mass and function can have significant implications for the risk of disease progression and long-term prognosis.

Enrollment: 216 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients diagnosed with malignant lymphomas, acute leukaemia and multiple myeloma referred to treatment at the Department of Haematology, Rigshospitalet.

Exclusion criteria

• Age: <18
• Pregnancy
• Physical or mental disabilities precluding test of muscle function
• Inability to read and understand Danish.

Trial design

216 participants in 3 patient groups

Cohort I - Patients newly diagnosed with malignant lymphoma (n=72)

Description:

These patients will undergo two assessments: A baseline-assessment prior to treatment for the hematologic cancer disease and a follow-up assessment at 6 months after treatment start

Cohort II - Patients newly diagnosed with acute leukaemia (n=72)

Description:

These patients will undergo two assessments: A baseline-assessment prior to treatment for the hematologic cancer disease and a follow-up assessment at 6 months after treatment start

Cohort III - Patients newly diagnosed with multiple myeloma (n=72)

Description:

These patients will undergo two assessments: A baseline-assessment prior to treatment for the hematologic cancer disease and a follow-up assessment at 6 months after treatment start